Skip to main content
Top
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

Epidermal growth factor receptor structural alterations in gastric cancer

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

EGFR overexpression has been described in many human tumours including gastric cancer. In NSCLC patients somatic EGFR mutations, within the kinase domain of the protein, as well as gene amplification were associated with a good clinical response to EGFR inhibitors. In gastric tumours data concerning structural alterations of EGFR remains controversial. Given its possible therapeutic relevance, we aimed to determine the frequency and type of structural alterations of the EGFR gene in a series of primary gastric carcinomas.

Methods

Direct sequencing of the kinase domain of the EGFR gene was performed in a series of 77 primary gastric carcinomas. FISH analysis was performed in 30 cases. Association studies between EGFR alterations and the clinical pathological features of the tumours were performed.

Results

Within the 77 primary gastric carcinomas we found two EGFR somatic mutations and several EGFR polymorphisms in exon 20. Six different intronic sequence variants of EGFR were also found. Four gastric carcinomas showed balanced polysomy or EGFR gene amplification. We verified that gastric carcinoma with alterations of EGFR (somatic mutations or copy number variation) showed a significant increase of tumour size (p = 0.0094) in comparison to wild-type EGFR carcinomas.

Conclusion

We demonstrate that EGFR structural alterations are rare in gastric carcinoma, but whenever present, it leads to tumour growth. We considered that searching for EGFR alterations in gastric cancer is likely to be clinically important in order to identify patients susceptible to respond to tyrosine kinase inhibitors.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pisani P, Parkin DM, Bray F, Ferlay J: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999, 83 (1): 18-29. 10.1002/(SICI)1097-0215(19990924)83:1<18::AID-IJC5>3.0.CO;2-M.CrossRefPubMed Pisani P, Parkin DM, Bray F, Ferlay J: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999, 83 (1): 18-29. 10.1002/(SICI)1097-0215(19990924)83:1<18::AID-IJC5>3.0.CO;2-M.CrossRefPubMed
2.
go back to reference Abate-Shen C: Deregulated homeobox gene expression in cancer: cause or consequence?. Nat Rev Cancer. 2002, 2 (10): 777-785. 10.1038/nrc907.CrossRefPubMed Abate-Shen C: Deregulated homeobox gene expression in cancer: cause or consequence?. Nat Rev Cancer. 2002, 2 (10): 777-785. 10.1038/nrc907.CrossRefPubMed
3.
go back to reference Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell. 1990, 61 (2): 203-212. 10.1016/0092-8674(90)90801-K.CrossRefPubMed Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell. 1990, 61 (2): 203-212. 10.1016/0092-8674(90)90801-K.CrossRefPubMed
4.
go back to reference Klapper LN, Kirchbaum MH, Sela M, Yarden Y: Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res. 2000, 77: 25-79.CrossRefPubMed Klapper LN, Kirchbaum MH, Sela M, Yarden Y: Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res. 2000, 77: 25-79.CrossRefPubMed
5.
go back to reference David L, Seruca R, Nesland JM, Soares P, Sansonetty F, Holm R, Borresen AL, Sobrinho-Simoes M: c-erbB-2 expression in primary gastric carcinomas and their metastases. Mod Pathol. 1992, 5 (4): 384-390.PubMed David L, Seruca R, Nesland JM, Soares P, Sansonetty F, Holm R, Borresen AL, Sobrinho-Simoes M: c-erbB-2 expression in primary gastric carcinomas and their metastases. Mod Pathol. 1992, 5 (4): 384-390.PubMed
6.
go back to reference Berger MS, Greenfield C, Gullick WJ, Haley J, Downward J, Neal DE, Harris AL, Waterfield MD: Evaluation of epidermal growth factor receptors in bladder tumours. Br J Cancer. 1987, 56 (5): 533-537.CrossRefPubMedPubMedCentral Berger MS, Greenfield C, Gullick WJ, Haley J, Downward J, Neal DE, Harris AL, Waterfield MD: Evaluation of epidermal growth factor receptors in bladder tumours. Br J Cancer. 1987, 56 (5): 533-537.CrossRefPubMedPubMedCentral
7.
go back to reference Gullick WJ: Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull. 1991, 47: 87-98.PubMed Gullick WJ: Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull. 1991, 47: 87-98.PubMed
8.
go back to reference Lemoine NR, Hughes CM, Gullick WJ, Brown CL, Wynford-Thomas D: Abnormalities of the EGF receptor system in human thyroid neoplasia. Int J Cancer. 1991, 49 (4): 558-561. 10.1002/ijc.2910490414.CrossRefPubMed Lemoine NR, Hughes CM, Gullick WJ, Brown CL, Wynford-Thomas D: Abnormalities of the EGF receptor system in human thyroid neoplasia. Int J Cancer. 1991, 49 (4): 558-561. 10.1002/ijc.2910490414.CrossRefPubMed
9.
go back to reference Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A, Schlessinger J: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature. 1985, 313: 144-147. 10.1038/313144a0.CrossRefPubMed Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A, Schlessinger J: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature. 1985, 313: 144-147. 10.1038/313144a0.CrossRefPubMed
10.
go back to reference Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995, 19: 183-232. 10.1016/1040-8428(94)00144-I.CrossRefPubMed Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995, 19: 183-232. 10.1016/1040-8428(94)00144-I.CrossRefPubMed
11.
go back to reference Tillotson JK, Rose DP: Endogenous secretion of epidermal growth factor peptides stimulates growth of DU145 prostate cancer cells. Cancer Lett. 1991, 60: 109-112. 10.1016/0304-3835(91)90216-5.CrossRefPubMed Tillotson JK, Rose DP: Endogenous secretion of epidermal growth factor peptides stimulates growth of DU145 prostate cancer cells. Cancer Lett. 1991, 60: 109-112. 10.1016/0304-3835(91)90216-5.CrossRefPubMed
12.
go back to reference Mateus AR, Seruca R, Machado JC, Keller G, Oliveira MJ, Suriano G, Luber B: EGFR regulates RhoA-GTP dependent cell motility in E-cadherin mutant cells. Hum Mol Genet. 2007, 16 (13): 1639-1647. 10.1093/hmg/ddm113.CrossRefPubMed Mateus AR, Seruca R, Machado JC, Keller G, Oliveira MJ, Suriano G, Luber B: EGFR regulates RhoA-GTP dependent cell motility in E-cadherin mutant cells. Hum Mol Genet. 2007, 16 (13): 1639-1647. 10.1093/hmg/ddm113.CrossRefPubMed
13.
go back to reference Hynes NE, Lane HA: ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer. 2005, 5: 341-354. 10.1038/nrc1609.CrossRefPubMed Hynes NE, Lane HA: ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer. 2005, 5: 341-354. 10.1038/nrc1609.CrossRefPubMed
14.
go back to reference Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Oimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004, 350: 2129-2139. 10.1056/NEJMoa040938.CrossRefPubMed Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Oimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004, 350: 2129-2139. 10.1056/NEJMoa040938.CrossRefPubMed
15.
go back to reference Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Linderman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004, 04: 1497-1500. 10.1126/science.1099314.CrossRef Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Linderman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004, 04: 1497-1500. 10.1126/science.1099314.CrossRef
16.
go back to reference Mu XL, Li LY, Zhang XT, Wang MZ, Feng RE, Cui QC, Zhou HS, Guo BQ: Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer. Clin Cancer Res. 2005, 11 (12): 4289-4294. 10.1158/1078-0432.CCR-04-2506.CrossRefPubMed Mu XL, Li LY, Zhang XT, Wang MZ, Feng RE, Cui QC, Zhou HS, Guo BQ: Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer. Clin Cancer Res. 2005, 11 (12): 4289-4294. 10.1158/1078-0432.CCR-04-2506.CrossRefPubMed
18.
go back to reference Schlessinger J: Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell. 2002, 110: 669-672. 10.1016/S0092-8674(02)00966-2.CrossRefPubMed Schlessinger J: Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell. 2002, 110: 669-672. 10.1016/S0092-8674(02)00966-2.CrossRefPubMed
19.
go back to reference Hirao T, Sawada H, Koyama F, Watanabe A, Yamada Y, Sakaguchi T, Tatsumi M, Fujimoto H, Emoto K, Narikiyo M, Oridate N, Nakano H: Antisense epidermal growth factor receptor delivered by adenoviral vector blocks tumor growth in human gastric cancer. Cancer Gene Ther. 1999, 6 (5): 423-427. 10.1038/sj.cgt.7700058.CrossRefPubMed Hirao T, Sawada H, Koyama F, Watanabe A, Yamada Y, Sakaguchi T, Tatsumi M, Fujimoto H, Emoto K, Narikiyo M, Oridate N, Nakano H: Antisense epidermal growth factor receptor delivered by adenoviral vector blocks tumor growth in human gastric cancer. Cancer Gene Ther. 1999, 6 (5): 423-427. 10.1038/sj.cgt.7700058.CrossRefPubMed
20.
go back to reference Becker JC, Muller-Tidow C, Stolte M, Fujimori T, Tidow N, Ilea AM, Brandts C, Tickenbrock L, Serve H, Berdel WE, Domschke W, Pohle T: Acetylsalicylic acid enhances antiproliferative effects of the EGFR inhibitor gefitinib in the absence of activating mutations in gastric cancer. Int J Oncol. 2006, 29 (3): 615-623.PubMed Becker JC, Muller-Tidow C, Stolte M, Fujimori T, Tidow N, Ilea AM, Brandts C, Tickenbrock L, Serve H, Berdel WE, Domschke W, Pohle T: Acetylsalicylic acid enhances antiproliferative effects of the EGFR inhibitor gefitinib in the absence of activating mutations in gastric cancer. Int J Oncol. 2006, 29 (3): 615-623.PubMed
21.
go back to reference Takehana T, Kunitomo K, Suzuki S, Kono K, Fujii H, Matsumoto Y, Ooi A: Expression of epidermal growth factor receptor in gastric carcinomas. Clin Gastroenterol Hepatol. 2003, 1 (6): 438-445. 10.1016/S1542-3565(03)00219-2.CrossRefPubMed Takehana T, Kunitomo K, Suzuki S, Kono K, Fujii H, Matsumoto Y, Ooi A: Expression of epidermal growth factor receptor in gastric carcinomas. Clin Gastroenterol Hepatol. 2003, 1 (6): 438-445. 10.1016/S1542-3565(03)00219-2.CrossRefPubMed
22.
go back to reference Tokunaga A, Onda M, Okuda T, Teramoto T, Fujita I, Mizutani T, Kiyama T, Yoshiyuki T, Nishi K, Matsukura N: Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer. 1995, 75 (6 Suppl): 1418-1425. 10.1002/1097-0142(19950315)75:6+<1418::AID-CNCR2820751505>3.0.CO;2-Y.CrossRefPubMed Tokunaga A, Onda M, Okuda T, Teramoto T, Fujita I, Mizutani T, Kiyama T, Yoshiyuki T, Nishi K, Matsukura N: Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer. 1995, 75 (6 Suppl): 1418-1425. 10.1002/1097-0142(19950315)75:6+<1418::AID-CNCR2820751505>3.0.CO;2-Y.CrossRefPubMed
23.
go back to reference Hirono Y, Tsugawa K, Fushida S, Ninomiya I, Yonemura Y, Miyazaki I, Endou Y, Tanaka M, Sasaki T: Amplification of epidermal growth factor receptor gene and its relationship to survival in human gastric cancer. Oncology. 1995, 52 (3): 182-188.CrossRefPubMed Hirono Y, Tsugawa K, Fushida S, Ninomiya I, Yonemura Y, Miyazaki I, Endou Y, Tanaka M, Sasaki T: Amplification of epidermal growth factor receptor gene and its relationship to survival in human gastric cancer. Oncology. 1995, 52 (3): 182-188.CrossRefPubMed
24.
go back to reference Tsugawa K, Yonemura Y, Hirono Y, Fushida S, Kaji M, Miwa K, Miyazaki I, Yamamoto H: Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology. 1998, 55 (5): 475-481. 10.1159/000011898.CrossRefPubMed Tsugawa K, Yonemura Y, Hirono Y, Fushida S, Kaji M, Miwa K, Miyazaki I, Yamamoto H: Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology. 1998, 55 (5): 475-481. 10.1159/000011898.CrossRefPubMed
25.
go back to reference Mammano E, Belluco C, Sciro M, Mencarelli R, Agostini M, Michelotto M, Marchet A, Nitti D: Epidermal growth factor receptor (EGFR): mutational and protein expression analysis in gastric cancer. Anticancer Res. 2006, 26 (5A): 3547-3550.PubMed Mammano E, Belluco C, Sciro M, Mencarelli R, Agostini M, Michelotto M, Marchet A, Nitti D: Epidermal growth factor receptor (EGFR): mutational and protein expression analysis in gastric cancer. Anticancer Res. 2006, 26 (5A): 3547-3550.PubMed
26.
go back to reference Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J, Benedetti JK, Baker AF, Hackett CB, Urba SG, Zaner KS, Blanke CD, Abbruzzese JL: Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol. 2006, 24 (30): 4922-4927. 10.1200/JCO.2006.07.1316.CrossRefPubMed Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J, Benedetti JK, Baker AF, Hackett CB, Urba SG, Zaner KS, Blanke CD, Abbruzzese JL: Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol. 2006, 24 (30): 4922-4927. 10.1200/JCO.2006.07.1316.CrossRefPubMed
27.
go back to reference Mimori K, Nagahara H, Sudo T, Ishii H, Yamashita K, Barnard GF, Mori M: The epidermal growth factor receptor gene sequence is highly conserved in primary gastric cancers. J Surg Oncol. 2006, 93 (1): 44-46. 10.1002/jso.20426.CrossRefPubMed Mimori K, Nagahara H, Sudo T, Ishii H, Yamashita K, Barnard GF, Mori M: The epidermal growth factor receptor gene sequence is highly conserved in primary gastric cancers. J Surg Oncol. 2006, 93 (1): 44-46. 10.1002/jso.20426.CrossRefPubMed
Metadata
Title
Epidermal growth factor receptor structural alterations in gastric cancer
Publication date
01-12-2008
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-10

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine